Original Article

Cinacalcet ameliorates aortic calcification in uremic rats via suppression of endothelial-to-mesenchymal transition

Min WU, Rì-ning TANG, Hong LIU, Ming-ming PAN, Bi-cheng LIU*

Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing 210009, China

**Aim:** Experimental studies found that cinacalcet (CINA) markedly attenuated vascular calcification in uremic rats, but its underlying mechanisms are still largely unknown. Recent evidence have demonstrated that endothelial cells (ECs) participate in ectopic calcification in part by mediating endothelial-to-mesenchymal transition (EndMT). In this study, we investigated whether CINA ameliorated aortic calcification in uremic rats via suppression of EndMT.

**Methods:** Uremia was induced in rats by feeding rats a 0.75% adenine diet for 4 weeks. After adenine withdrawal, the rats were maintained on a 1.03% phosphorus diet for next 8 weeks. At initiation of the adenine diet, rats were orally administered CINA (10 mg/kg one day) for 12 weeks. The aortic expression of EndMT- and chondrocyte-markers was examined. The effect of elevated PTH on EndMT was also studied in aortic ECs.

**Results:** In uremic rats, CINA treatment significantly decreased the serum PTH concentrations, but did not affect the elevated levels of serum calcium (Ca), phosphorus (P) and Ca×P product. Besides, CINA significantly attenuated aortic calcification, and inhibited the expression of chondrocyte markers (SOX9 and COL2A1) and chondrocyte proteoglycan in uremic aortas. Moreover, CINA treatment largely abolished the up-regulation of mesenchymal markers (FSP1 and α-SMA) and down-regulation of the endothelial marker (CD31), which accompanied aortic calcification in uremic aorta samples. In vitro, PTH increased the expression of EndMT-markers in a concentration- and time-dependent manner.

**Conclusion:** These findings suggest that strategies aiming at reducing serum PTH might prevent uremic aortic calcification by abrogating EndMT.

**Keywords:** cinacalcet; uremia; aortic calcification; endothelial cells; parathyroid hormone; endothelial-to-mesenchymal transition

Introduction

Cardiovascular disease is the primary cause of mortality in patients with chronic kidney disease (CKD)1-2. Numerous studies have demonstrated that vascular calcification (VC) is a common feature in CKD patients and that it contributes to the development of cardiovascular events3. As a pathologic process, VC could be mediated by mechanical, neurohor-monal, inflammatory and/or oxidative stress-associated factors4-5. Secondary hyperparathyroidism, characterized by elevated serum parathyroid hormone (PTH) concentrations, is a frequent component of the natural progression of CKD6. Although the effect of PTH on mineral metabolism has been well established, experimental and clinical evidence indicates that PTH is also causally involved in the pathogenesis of VC in CKD7-9.

Considering the detrimental effects of elevated PTH, strategies aimed at lowering serum PTH levels are frequently prescribed in patients with CKD. Cinacalcet (CINA), a calcimimetic agent, reduces PTH levels without increasing circulating levels of calcium and phosphorus10-12. Meanwhile, emerging studies suggested that suppression of PTH by CINA markedly attenuated vascular remodeling and calcification in uermia13-16. However, the underlying mechanisms of this action are still largely unknown.

Studies using transgenic lineage-tracing techniques have demonstrated that the endothelial cells (ECs) contribute to calcified lesions via the endothelial-to-mesenchymal transition (EndMT)17-20. These results suggest that blockade of EndMT might be a novel therapeutic target for VC21,22. However, whether suppression of serum PTH concentrations by CINA could ameliorate EndMT in vascular calcification is still unknown. In the present study, we investigated the effect of
CINA on aortic EndMT in uremia.

Materials and methods

Cell culture
Primary human aortic endothelial cells (HAECs) were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA) and cultured as previously described. Briefly, cells were grown in endothelial culture medium (Nl 1001, ScienCell) containing 5% fetal bovine serum (FBS) (Nl 0025, ScienCell), 1% endothelial cell growth supplement (Nl 1052, ScienCell) and 1% penicillin/streptomycin solution (Nl 0503, ScienCell) in 5% CO2 at 37°C. HAECs between passages 3–5 were expanded in monolayers in culture flasks or dishes. At approximately 80% confluence, the culture medium was changed to a serum-free solution for 24 h prior to use of the HAECs in all experiments. Human recombinant PTH fragment 1–34 (P3796, Sigma, USA) was then added to the serum-free culture medium.

Animals
Study protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Southeast University (Nanjing, China). The rat model of uremia and secondary hyperparathyroidism was established as previously described. Briefly, 8-week-old male Wistar rats (SLAC Laboratory Animal Co Ltd, China) were randomly divided into three groups: the control group (C, n=8), the uremia group (U, n=8) and the CINA-treated uremia group (U+CINA, n=8). Uremia was induced by feeding rats a 0.75% adenine diet for 4 weeks. Rats that were fed the diet without adenine served as controls. After adenine withdrawal, all animals were maintained on a 1.03% phosphorus diet for next 8 weeks. At initiation of the adenine diet, rats in the U+CINA group were administered CINA (sc-207438, Santa Cruz Biotechnology, USA) orally once daily (10 mg/kg) until the time of killing. Based on exposure levels, the dose equivalent to 10 mg/kg is 60 mg, which is the clinically used dosage. Blood samples were taken to assess biochemical parameters, and aorta samples were used for histology.

Serum biochemistry
Serum total calcium (Ca) and phosphorus (P) concentrations were measured at Zhongda Hospital, Southeast University School of Medicine using an autoanalyzer system (Hitachi, Japan). Serum parathyroid hormone (PTH) levels were determined using ELISA assays (Lengton, China).

Histology and immunohistochemical staining
Paraffin-embedded rat aorta sections (3-μm thick) were prepared using a routine procedure. The sections were subjected to von kossa staining for assessing calcified lesions. Immunohistochemical staining was performed according to a routine protocol. The antibodies used were as follows: CD31 (sc-1506, Santa Cruz, USA), FSP1 (ab-27957, Abcam, Hong Kong, China), SOX9 (ab185230, Abcam) and COL2A1 (sc-52658, Santa Cruz, USA). For the negative controls, the specific primary antibody was replaced with phosphate-buffered saline.

Immunofluorescence staining
Cryosections (5-μm thick) or coverslips were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X-100 and blocked with 10% bovine serum albumin (BSA) in phosphate-buffered saline at room temperature. The slides were then immunostained with primary antibodies against CD31 (sc-1506) and FSP1 (ab-27957) at 4°C overnight. After incubation with a mixture of the two secondary antibodies for 1 h in the dark at room temperature, images were captured using a laser scanning confocal microscope (LSM 510 META, Zeiss, Germany).

Real-time PCR
Total RNA was extracted using RNAiso Plus according to the manufacturer's instructions (TAKARA, China). The RNA concentration and purity were confirmed with a Nanodrop 2000 (Thermo, USA). Samples with a relative absorbance ratio at 260/280 between 1.8 and 2.0 were used. All RNA samples were reverse transcribed (Applied Biosystems, USA). The quantification of specific mRNAs was performed using an ABI Prism 7300 Sequence Detection System (Applied Biosystems, USA) with the SYBR Green Real-time PCR Kit (TAKARA, China). The relative amount of mRNA was normalized to β-actin and calculated using the standard curve method. Briefly, the pre-PCR product of each gene was used as the standard. The standard curve was established with a 10-fold serial dilution of the product and was included in all PCR runs. The ratio of target gene abundance/housekeeping gene abundance was used to evaluate the expression level of each gene. Controls containing ddH2O were confirmed to be negative in all runs.

Western blot analysis
Equal amounts of the protein obtained from each lysate were electrophoresed in a 4%–20% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane (Pall, USA) by electroblotting. The blots were incubated overnight with primary antibodies against CD31 (sc-1506), FSP1 (ab-27957), α-SMA (ab5694), SOX9 (ab185230) and COL2A1 (sc-52658) followed by incubation with a horseradish peroxidase-labeled secondary IgG antibody (Santa Cruz). The signals were detected using an advanced ECL system (GE Healthcare, UK). β-Actin was used as an internal control.

Statistical analysis
Data are expressed as mean±standard deviation (SD). Statistical analyses were performed with one-way analysis of variance (ANOVA) followed by Bonferroni correction using SPSS 16.0 statistical software. A value of P<0.05 was considered to be statistically significant.

Results
Physical and metabolic parameters of animals
As shown in Figure 1, serum Ca levels decreased, whereas
serum P levels and the Ca×P product increased in the uremia (U) group compared with controls (CTL). Following CINA treatment, the serum Ca, P and Ca×P product levels in rats with uremia were maintained at low levels, but the differences were not statistically significant (Figure 1B–1D). Compared with the control group, serum PTH concentrations were markedly elevated in uremic rats, which were significantly attenuated by the administration of CINA (Figure 1A).

CINA treatment ameliorated aortic calcification and the expression of chondrocyte markers in uremic rat models

As determined by von Kossa staining, the area of calcified lesions in the aortas of the U group was significantly increased compared to controls, but was decreased by treatment with CINA (Figure 2). As determined by alcian blue staining, levels of chondrocyte proteoglycans were markedly elevated in rats from the U group compared with the CTL group, whereas this induction was partially abolished by CINA treatment (Figure 3A). Calcium accumulation, a late chondrogenic marker, increased in the uremic aortas compared to the controls as detected by alizarin red staining, which was largely inhibited by CINA treatment (Figure 3B). These results were consistent with the results obtained by von Kossa staining (Figure 2). As shown in Figure 3C and 3D, illustrated by real-time PCR and Western blot, mRNA and protein levels of chondrocyte specific markers were markedly up-regulated in the rats with uremia. This induction was suppressed by the treatment with CINA.

**Figure 1.** Analysis of (A) serum PTH concentrations, (B) Ca, (C) P and (D) Ca×P product in the study groups. The data are expressed as the mean±SD (n=6 for each group). ①P<0.05 vs the CTL group. ②P<0.05 vs the U group. CTL, control; U, uremia; CINA, cinacalcet.

**Figure 2.** CINA ameliorates aortic calcification in rats with uremia. (A) Representative micrographs demonstrate calcified lesions in aorta samples from different groups of rats, as indicated. Aorta sections were subjected to von Kossa staining. (B) Semi-quantitative determination of aortic calcification in the different groups. The data are expressed as the mean±SD (n=6 for each group). ①P<0.05 vs the CTL group. ②P<0.05 vs the U group. CTL, control; U, uremia; CINA, cinacalcet.
CINA treatment ameliorated aortic EndMT in uremic rat models

As determined by real-time PCR and Western blot analysis, mRNA and protein levels of the endothelial cell marker CD31 were dramatically decreased in aorta tissues from the U group compared with controls, but CD31 expression was partially restored by CINA treatment (Figure 4A–4C). By contrast, aortic FSP1 expression was significantly augmented in the U group compared to controls, an effect that was largely inhibited by CINA treatment (Figure 4A–4C). Moreover, confocal microscopy revealed an increased co-localization of CD31 and FSP1 (yellow) in aortas from the U group compared with controls, and administration of CINA abrogated this change (Figure 4D).

PTH induced EndMT in cultured HAECs

Considering that similar serum Ca and P levels were observed in the U and U+CINA groups, the different histological findings in the aorta of these two groups can most likely be attributed to differences in PTH exposure. To further confirm the effect of elevated PTH on inducing EndMT, we next performed in vitro experiments using HAECs. As PTH (1–34) is the shortest fragment with the same biological effect as the intact PTH, commercially available PTH (1–34) was used to treat cultured HAECs. The results of real-time PCR showed that PTH incubation led to a significant decrease in the mRNA expression of CD31 and an increase in the mRNA levels of FSP1 and α-SMA at 48 h post-treatment (Figure 5A–5C). In addition, HAECs were treated with 10^{-8} mol/L PTH for various periods of time, and the results indicated that PTH caused a significant decrease in CD31 mRNA expression and an increase in FSP1 and α-SMA mRNA levels from 0–48 h post-treatment (Figure 5D–5F). As determined by Western blot, PTH caused a significant decrease in the protein level of CD31, as well as subsequent increases in the protein expression levels.
of FSP1 and α-SMA, in a concentration- and time-dependent manner (Figure 6). Confocal microscopy detected that cells treated with $10^{-8}$ mol/L PTH for 48 h acquired FSP1 staining and lost CD31 staining compared with the control cells (Figure 7A). As observed by inverted microscopy, some PTH-treated cells showed a distinct change from a cobblestone-like to a spindle-shaped morphology (Figure 7B). These data suggest that PTH induces EndMT in cultured HAECs.

**Discussion**

Serum PTH concentrations are progressively increased as renal function declines, and this elevation of PTH plays an important role in both the pathogenesis of bone mineral disease and in the development of various complications in uremia[25, 26]. Recent studies have demonstrated the involvement of PTH in the development of calcified lesions, and strategies lowering PTH levels, including calcimimetics and parathyroidectomy, attenuate the progression of vascular calcification in CKD patients and uremic animal models[27–30]. A number of studies have shown that suppression of PTH by CINA can significantly ameliorate VC in CKD[15].

It is known that calcified lesion is a fundamental component of the adverse structural remodeling of vasculature present in uremia[31]. Currently, uremic VC is recognized to be a cell-regulated process with similarities to cartilage formation driven by chondrogenic cells[32, 33]. Recently, evidence from clinical and experimental investigations revealed the involvement of EndMT in the development of ectopic calcification in pathological settings, including diabetes, prostate tumor and fibrodysplasia ossificans progressive (FOP)[17, 18, 34]. These studies suggest that ECs directly contribute to VC via EndMT. In the present study, our data showed that CINA treatment attenuated aortic EndMT in the adenine-induced uremic rat model. Meanwhile, biochemical analysis indicated PTH concentrations were markedly suppressed by CINA in rats with

---

**Figure 4.** CINA attenuates the expression of EndMT-related markers in aortas of uremic rats. (A) Real-time PCR results showing aortic mRNA expression of CD31 and FSP1 in the different groups of rats, as indicated. (B, C) Western blot analyses showing cardiac protein expression of CD31 and FSP1 in the different groups of rats, as indicated. Representative Western blots (B) and quantitative determination of protein levels (C) are presented. (D) Representative micrographs showing aortic double-labeling of CD31 and FSP1 in the different groups, as indicated (Scale bar, 20 μm). *P<0.05 vs the CTL group. *P<0.05 vs the U group. CTL, control; U, uremia; CINA, cinacalcet.
uremia. Moreover, in vitro study further showed that elevated PTH levels induced the expression of EndMT-related markers in a concentration- and time-dependent manner. Therefore, we propose that the beneficial efficacy of CINA in improving VC and EndMT could most likely be attributed to decrease on PTH exposure. This result was consistent with the work by Jung et al, which demonstrated that the effect of CINA on reducing VC was attributed to its suppression of PTH levels[15].

In conclusion, elevation of PTH induces EndMT and contributes to aortic calcification in uremic rats, which could be prevented by CINA treatment. These results suggest that strategies aimed at lowering PTH levels might exert vascular protective effects through an anti-EndMT mechanism.

Acknowledgements
These studies were supported by grants from the National Natural Science Foundation of China (81130010, 81470997, 31571186, and 81500545), Natural Science Foundation of Jiangsu Province (BK20150640) and Clinic Research Center of Jiangsu Province (BL2014080).

Author contribution
Min WU, Ri-ning TANG, and Bi-cheng LIU designed research; Min WU, Ming-ming PAN, and Hong LIU conducted experiments; Min WU, Ri-ming TANG, and Hong LIU performed data analysis; Min WU, Ri-ning TANG, and Bi-cheng LIU wrote the manuscript.

References
1 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305.
2 Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanism, and prevention. Lancet 2013; 382: 339–52.
3 Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010; 7: 528–36.
4 Demer LL, Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol 2014; 34: 715–23.
5 Byon CH, Javed A, Dai Q, Clemens TL, Darley-Usmar VM, McDonald...
JM, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008; 283: 15319–27.

6 Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6: 913–21.

7 Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhães AO, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 7: 1262–70.

8 Custódio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, et al. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant 2012; 27: 1437–45.

9 Malluche HH, Blomquist G, Monier-Faugere MC, Cantor TL, Davenport DL. High parathyroid hormone level and osteoporosis predict progression of coronary artery calcification in patients on dialysis. J

Figure 6. Effect of PTH on protein expression of CD31, FSP1 and α-SMA in HAECs. (A–C) HAECs were incubated for 48 h with increasing concentrations of PTH. (D–F) HAECs were incubated with PTH (10⁻⁸ mol/L) for different periods, as indicated. The protein expression levels were determined by Western blot. The data are expressed as the mean±SD (n=3 to 5). *P<0.05 vs 0 group.
Am Soc Nephrol 205; 26: 2534–44.

10 Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800–7.

11 Bover J, Perez R, Molina M, Benavides B, Ariza F, Miguel JL, et al. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice. Nephron Clin Pract 2011; 118: c109–21.

12 Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Fioege J, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab 2013; 98: 4834–44.

13 Kawata T, Nagano N, Ohi M, Miyata S, Koyama C, Kobayashi N, et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008; 74: 1270–7.

14 Joki N, Nikolov IG, Caudriller A, Mentaverri R, Massy ZA, Drüeke TB. Effect of calcimimetic on vascular calcification and atherosclerosis in uremic mice. Bone 2009; 45: S30–4.

15 Jung S, Querfeld U, Müller D, Rudolph B, Peters H, Krämer S. Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats. J Hypertens 2012; 30: 2182–91.

16 Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327–39.

17 Medici D, Shore EM, Lounet VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 2010; 16: 1400–6.

18 Yao Y, Jumabay M, Ly A, Radparvar M, Cubberly MR, Bostrom KI. A role for the endothelium in vascular calcification. Circ Res 2013; 113: 495–504.

19 Mahler GJ, Farrar EJ, Butcher JT. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33: 121–30.

20 Yao J, Gulhard PJ, Blazquez-Medela AM, Guo Y, Moon JH, Jumabay M, et al. Serine protease activation essential for endothelial-mesenchymal transition in vascular calcification. Circ Res 2015; 117: 758–69.

21 Tang R, Li Q, Lv L, Dai H, Zheng M, Ma K, et al. Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells. Cardiovasc Diabetol 2010; 9: 31.

22 De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach
K, et al. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 2013; 83: 1109–17.

23 Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1370–7.

24 Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 2007; 292: F1215–8.

25 Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, Rodríguez-Puyol D, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 266: 1938–47.

26 Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL. Plasma parathyroid hormone level and prevalent cardiovascular disease in stages 3 and 4: an analysis from the Kidney Early evaluation Program (KEEP). Am J Kidney Dis 2009; 53: S3–10.

27 Schaefer B, Schlosser K, Wuhl E, Schall P, Klaus G, Schaefer F, et al. Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease. Nephrol Dial Transplant 2010; 25: 2590–5.

28 Iwamoto N, Sato N, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, et al. Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients. Clin Exp Nephrol 2015. doi: 10.1007/s10157-015-1208-x

29 Di Lallo L, Gorini A, Bellasi A, Morrone LF, Rivera R, Russo L, et al. Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease. Clin Kidney J 2015; 8: 732–6.

30 Malluche HH, Blomquist G, Monier-Faugere MC, Cantor TL, Davenport DL. High parathyroid hormone level and osteoporosis predict progression of coronary artery calcification in patients on dialysis. J Am Soc Nephrol 2015; 26: 2534–44.

31 Paloian NJ, Giachelli CM. A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol 2014; 307: F891–900.

32 Tompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 2012; 8: 529–43.

33 Padoian NJ, Giachelli CM. A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol 2014; 307: F891–990.

34 Dudley AC, Khan ZA, Shih SC, Kang SY, Zwaans BM, Bischoff J, et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell 2008; 14: 201–11.